ARQ 092 and ARQ 751 potency.

Figshare2015-12-03 更新2026-04-29 收录

靶点抑制活性

AKT抑制剂

数据链接：

https://figshare.com/articles/dataset/_ARQ_092_and_ARQ_751_potency_/1576858 数据链接链接失效反馈

官方服务：

资源简介：

The biochemical IC50 values for ARQ 092, ARQ 751, MK-2206, and GDC-0068 were determined against full-length active form of AKT1, 2, and 3.ARQ 092 and ARQ 751 potency.

创建时间：

2015-12-03

DeepADRA2A: predicting adrenergic α2a inhibitors using deep learning

AI辅助药物设计

靶点抑制活性

Adrenergic α2a (ADRA2A) receptors play a crucial role in modulating various physiological actions, thereby influencing the proper functioning of different systems in the body. ADRA2A regulation is ass

Taylor & Francis Group2024-11-21 更新50

Quinolone Resistance in Staphylococci: Activities of New Nonfluorinated Quinolones against Molecular Targets in Whole Cells and Clinical Isolates

抗菌素耐药性

靶点抑制活性

The activity of three new, 8-methoxy-nonfluorinated quinolones (NFQs) against multiple-drug-resistant staphylococci was investigated. First, using Staphylococcus aureus strains containing point mutati

PubMed Central30

AKT antagonist AZD5363 influences estrogen receptor function in endocrine resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo. Homo sapiens

内分泌治疗耐药性

AKT抑制剂

Phosphoinositide-3-kinase/protein-kinaseB/mammalian target of rapamycin (PI3K/AKT/mTOR) signalling plays an important role in breast cancer (BC). Its interaction with estrogen receptor (ER) signalling

NIAID Data Ecosystem20

Reversal of glucocorticoid resistance by AKT inhibition in T-ALL

T-ALL糖皮质激素耐药

AKT抑制剂

Glucocorticoid resistance is a major driver of therapeutic failure in T-cell acute lymphoblastic leukemia (T-ALL). Here we used a systems biology approach, based on the reverse engineering of signali

NIAID Data Ecosystem40

AKT antagonist AZD5363 influences estrogen receptor function in endocrine resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo

乳腺癌耐药性

AKT抑制剂

NIAID Data Ecosystem30